30
Participants
Start Date
January 15, 2017
Primary Completion Date
June 1, 2021
Study Completion Date
June 1, 2021
Anlotinib
"Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.~Stereotactic Radiosurgery Stereotactic Radiosurgery as the initial treatment of non small cell lung cancer patients with limited brain metastases"
Department of Radiation Oncology Cancer Center, Peking University Third Hospital 49# North Garden Rd.,Haidian Dist., Beijing
Huashan Hospital
OTHER
Tianjin Medical University
OTHER
Peking University Third Hospital
OTHER